Telomere length across the spectrum of metabolic health: an analysis from the LIPIDOGEN2015 study

Maciej Banach; Martyna Fronczek; Anna Goc; Mateusz Lejawa; Ewa Boniewska-Bernacka; Tadeusz Osadnik; Anna Pańczyszyn; Joanna K Strzelczyk; Natalia Pawlas; Marek Gierlotka; Marcin Goławski; Karol Krystek; Agnieszka Gach; Kamila Osadnik; Jacek Jóźwiak

doi:10.5114/aoms/195465

Telomere length across the spectrum of metabolic health: an analysis from the LIPIDOGEN2015 study

Arch Med Sci. 2024 Oct 31;21(4):1213-1221. doi: 10.5114/aoms/195465. eCollection 2025.

Authors

Affiliations

¹ Faculty of Medicine, the John Paul II Catholic University of Lublin, Poland.
² Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland.
³ Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
⁴ Department of Biology and Genetics, Institute of Medical Sciences, University of Opole, Poland.
⁵ Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
⁶ Department of Cardiology, Institute of Medical Sciences, University of Opole, Poland.
⁷ Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
⁸ Department of Family Medicine and Public Health, Institute of Medical Sciences, University of Opole, Poland.

Abstract

Introduction: Telomere length is a cellular aging marker and correlates with various cardiovascular disease (CVD) risk factors. The current study assessed the association between obesity, metabolic syndrome (MetS), and telomere length.

Material and methods: The LIPIDOGRAM&LIPIDOGEN2015 study was conducted in primary care in 2015-2016. Patients recruited to the LIPIDOGEN2015 cohort (n = 1788) were a random subset of patients of the LIPIDOGRAM2015 (n = 13,724) study. For the aims of this analysis, the recruited patients were divided into four groups based on the presence of MetS: healthy slim (HS), metabolically healthy obese (MHO), non-obese with MetS (NOMS), and metabolically unhealthy obese (MUO). Relative telomere length (RTL) was measured using quantitative polymerase chain reaction (qPCR).

Results: 1516 patients (85% of the total group; 59.7% female, mean age 50.3 years) were included in the final analyses. Increases in body mass index (BMI), waist circumference, prevalence of diabetes mellitus, hypertension, dyslipidemia, and history of myocardial infarction moving from HS to MUO were observed. The MUO group exhibited the highest triglyceride and lowest high-density lipoprotein (HDL-C) levels. In the univariate regression analyses, NOMS (p = 0.038) and MUO (p = 0.003) were associated with significantly decreased RTL. After adjusting for age, gender, education, smoking, place of residence, and myocardial infarction, the association was no longer statistically significant.

Conclusions: Despite the lack of statistical significance in the multivariate analysis, the univariate results suggest that both MUO and NOMS phenotypes contribute to the shortening of telomere length. These results may also indicate that MetS, irrespectively of obesity occurrence, is responsible for the shortened lifespan.

Keywords: longevity; metabolic health; metabolic syndrome; obesity; telomere length.